GlassScriptPhysician profile
Sarah W Hampton
NPI 1609872217
$2,501.51
in general payments reported to CMS, 2019-2025
27 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.31 · 2020: $239 · 2021: $583 · 2022: $572 · 2023: $402 · 2024: $332 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $825.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $244.56 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Genzyme Corporation | $154.50 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $149.59 | 2020-2023 | Seglentis, Livalo |
| Astrazeneca Pharmaceuticals LP | $128.27 | 2021-2025 | Airsupra, Breztri, Andexxa |
| Astellas Pharma US INC | $114.75 | 2021-2023 | Veozah |
| Ferring Pharmaceuticals INC. | $109.64 | 2025 | Adstiladrin |
| Regeneron Healthcare Solutions, INC. | $103.12 | 2021-2023 | Dupixent |
| Eisai INC. | $80.19 | 2020-2021 | |
| Abbvie INC. | $78.68 | 2021-2024 | |
| Organogenesis INC. | $71.57 | 2025 | Affinity, Via Matrix, Puraply Wound Matrix |
| Lilly USA, LLC | $58.01 | 2022-2024 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.26 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $42.74 | 2022-2023 | |
| Amgen INC. | $39.39 | 2024 | Repatha, Otezla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.07 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Biohaven Pharmaceuticals, INC. | $31.21 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $26.95 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $23.90 | 2025 | Auvelity |
| Averitas Pharma INC. | $22.42 | 2025 | Qutenza |
| Pfizer INC. | $20.70 | 2023 | |
| Almatica Pharma LLC | $20.42 | 2021 | |
| Allergan, INC. | $15.60 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.43 | 2020 | |
| Ucb, INC. | $13.77 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.66 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hampton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.